NOS3 and metabolic syndrome: This dysfunction is driven by oxidative stress, dyslipidemia, and pro-inflammatory cytokines, leading to reduced endothelial nitric oxide synthase (eNOS)–derived nitric oxide (NO) bioavailability, which impairs vasodilation and promotes pro-atherogenic changes in the arterial wall [14].